Vornorexant

Vornorexant
Vornorexant_skeletal.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Vornorexant is a medication that acts as a dual orexin receptor antagonist. It is primarily investigated for its potential use in the treatment of insomnia and other sleep disorders.

Mechanism of Action

Vornorexant works by selectively blocking the action of orexin neuropeptides. Orexins, also known as hypocretins, are neuropeptides that regulate arousal, wakefulness, and appetite. By inhibiting the binding of orexins to their receptors, Vornorexant promotes sleep by reducing wakefulness.

Pharmacokinetics

The pharmacokinetic profile of Vornorexant includes its absorption, distribution, metabolism, and excretion. After oral administration, Vornorexant is absorbed into the bloodstream and distributed throughout the body. It is metabolized primarily in the liver and excreted via the kidneys.

Clinical Trials

Vornorexant has undergone several clinical trials to evaluate its efficacy and safety in treating insomnia. These trials assess various parameters such as sleep onset latency, total sleep time, and sleep quality.

Side Effects

Common side effects of Vornorexant may include drowsiness, headache, and dizziness. As with any medication, it is important to monitor for adverse effects and consult a healthcare provider if they occur.

Potential Uses

While primarily studied for insomnia, Vornorexant may have potential applications in other conditions related to sleep disturbances, such as narcolepsy and shift work sleep disorder.

Related pages

• Orexin receptor antagonist
• Insomnia
• Sleep disorder

• Vornorexant
  Vornorexant